4/A - Celularity Inc (0001752828) (Issuer)

4/A - Celularity Inc (0001752828) (Issuer)

4/A - Celularity Inc (0001752828) (Issuer)

4/A - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

Oppenheimer downgraded Celularity from Outperform to Perform

H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

Truist downgraded Celularity from Buy to Hold and set a new price target of $10.00

Oppenheimer initiated coverage of Celularity with a rating of Outperform and set a new price target of $9.00

Morgan Stanley initiated coverage of Celularity with a rating of Equal-Weight and set a new price target of $9.00

Truist Securities initiated coverage of Celularity with a rating of Buy and set a new price target of $12.00

8-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

424B3 - Celularity Inc (0001752828) (Filer)

EFFECT - Celularity Inc (0001752828) (Filer)

S-1 - Celularity Inc (0001752828) (Filer)

EFFECT - Celularity Inc (0001752828) (Filer)

424B3 - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

S-1 - Celularity Inc (0001752828) (Filer)

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics. FLORHAM PARK, N.J., March 12, 2026

Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

Transaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunityOrganizational realignment reduces operating expenses and sharpens focus on longevity therapeutics FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close n

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unused New Jersey net operating losses (NOLs) and $1.9 Million of unused New Jersey research and development (R&D) tax credits. The NOLs and R&D tax credits sale was administered through New Jersey's Technology Business Tax Certificate Transfer Program, which enables qualified New Jersey-based technology and life science companies to sell their New Jersey NOLs and R&D tax credits for cash to buyers who purchase and

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare & Medicaid Services' (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026. On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. At the closing, Celularity received $10.00 million in gross proceeds. The transaction structure provides for the potential availability of up to an additional $2.0 million, subject to the satisfaction of specified closing conditions and the investor's election, as set forth in the definitive agreements. The financing includes a senior secur

The contemplated financing transactions would provide up to $12 Million in capital to support Celularity's strategic priorities around longevity and preservation of human performance. FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, a Los Angeles-based investment management firm. The contemplated financing transactions are continge

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. ("DefEYE"), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity's in-kind investment in DefEYE's $12MM Series Seed Preferred Equity funding round. DefEYE was established to build on Verséa Ophthalmics' commercial momentum, reflected in significant year-over-year sales growth since its August 2022 launch. According to DefEYE

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Florida physicians an important new tool in treating DFU patients. FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled "Human

FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi

Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol

FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera

FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C

Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancerAppointed Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer and announced the promotion of two senior executives and the formation of a new Executive CommitteePresenting an abstract at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting that supports the scientific rationale of the CYNK-101Strengthened balance sheet using a combination of a $150 million at-the-market (ATM) facility and a $150 million pre-paid advance agreement FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NAS

FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., has been appointed Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today. Dr. Kilcoyne brings over 15 years of clinical experience to Celularity, having previously served in R&D, medical affairs, and commercialization roles, primarily focused on oncology. He has a track record of advancing early-stage clinical programs through commercialization and will p

FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced the appointment of Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President effective today. Reporting to Robert J. Hariri, M.D., Ph.D., Chairperson and Chief Executive Officer, Dr. Pecora will provide senior leadership to advance Celularity's clinical pipeline toward U.S. Food and Drug Administration (FDA) approval, including responsibility for preclinical and clinical development and regulatory affairs. "It is with great pleasure that we announce Andrew's appointment as Celularity's P

SC 13D/A - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13D/A - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13D/A - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13G - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13G - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)